PerformanceResearch Market

IGF-1 DES

A truncated IGF-1 analog that remains a familiar name in performance and tissue-growth peptide discussions.

IGF-1Muscle GrowthGrowth FactorResearch Market

Also referenced as: IGF-1 DES(1-3)

Also appears in: GH axis

Tracked market history

What has the price actually done?

Daily, exact-comparability offers. Discounts use the terms known on each historical date.

Flatvs. Jul 30
Current low$99.00/mg
Market median$99.00/mg
Current coverage1 vendors
Observed window21 daily points
Lowest effective priceMarket median
Compare current offers
How this history is calculated

Effective price per mg uses an active dated override first, then the row-level historical discount, then the vendor default from the same Git revision. Aggregate chart points include exact-comparability offers only. Missing observations remain gaps; the series does not interpolate across unavailable offers or absent snapshots.

Price watch · beta

Let the market come to you.

Watch the best market price or one vendor. Get one email when IGF-1 DES crosses your target, drops, or sets a new tracked low—without daily noise.

Requires a confirmed Weekly Peptide Intel address, then a separate alert confirmation. Already watching? Manage price alerts. Public prices can change; confirm the final cart total.
Public product evidenceSearch the public certificate ledger for this compoundNo exact compound records are currently indexed under this profile name.
Status
Research Market

This name primarily lives in the research market and should not be read like an approved pharmaceutical product.

Research area
Performance / anabolic research

Primary research area: Performance. Also surfaces under GH axis for browsing and discovery.

Aliases
1

IGF-1 DES(1-3)

Signal depth
Low

No FDA label signal · 0 trials · 6 PubMed results

Preclinical
Research evidence

Current evidence for IGF-1 DES is limited to laboratory or animal studies — there are no name-matched human trials with reported results. Any claims about effects in people are not yet backed by clinical data.

IGF-1 DES has no clinical trials that name it and 6 PubMed-indexed publications and is not FDA-approved. Current evidence is preclinical or mechanistic.

Human data
Lab / animal only
Trial quality
No human trials
Outcomes
No human trials
Replication
Multiple papers
Literature
Established
Comparative StudyEnforced epithelial expression of IGF-1 causes hyperplastic prostate growth while negative selection is requisite for spontaneous metastogenesis.Comparative StudyIGF-I has a dual effect on insulin release from isolated, perifused adult rat islets of Langerhans.Journal ArticleThe effects of insulin-like growth factor (IGF)-1, IGF-2, and des-IGF-1 on neuronal loss after hypoxic-ischemic brain injury in adult rats: evidence for a role for IGF binding proteins.Comparative StudyThe direct in vitro effect of insulin-like growth factors (IGFs) on normal bovine mammary cell proliferation and production of IGF binding proteins.Journal ArticleA key functional role for the insulin-like growth factor 1 N-terminal pentapeptide.
Evidence history

Re-checked nightly against the registries — tracked since 2026-07-09. No band changes yet.

Grades evidence strength, not efficacy or safety. Research-use context; not medical advice. Graded 2026-09-08 from PubMed, ClinicalTrials.gov, ISRCTN, openFDA, Health Canada, and OpenAlex — computed deterministically and refreshed nightly, with a retraction check. How we grade →

What IGF-1 DES is

IGF-1 DES is a truncated analog of insulin-like growth factor 1, typically discussed in performance and tissue-growth circles rather than mainstream medicine.

Why it matters

It is still one of the more recognizable growth-factor names missing from many peptide libraries, especially for users who know the difference between growth hormone secretagogues and direct growth-factor analogs.

Regulatory context

IGF-1 DES is not FDA approved as a mainstream therapeutic product. It fits best in the research-market category.

Practical reading note

Because IGF-1 language sounds medical and familiar, this is one of the easier compounds for people to overread. The research-market versions are not the same as a broadly established drug pathway.